There's been a lot of talk in pharma circles about making sure that their drug development programmes and clinical trials are patient-centric – but what can be done for pe
Online patient communities have become a vital resource for rare disease patients, and pharma is coming round to the idea of engaging with them for real-world data.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh